Reporter brief
Pilot study assessed whether dasatinib and quercetin reach the brain in older adults with early Alzheimer's disease.
What happened
This pilot study investigated whether a combination of dasatinib and quercetin (D+Q) penetrates into the brain via cerebrospinal fluid in older adults with early Alzheimer's disease. The study was designed as a proof-of-concept to evaluate drug bioavailability in the brain, as prior evidence showed this combination affects dying cells in other chronic illnesses and in mouse models of Alzheimer's disease. No efficacy outcomes on Alzheimer's symptoms were reported in this preliminary phase.
Why it matters
Assessment pending; this report does not establish a change in evidence.
What it does NOT prove
- Limitations have not been recorded; consult the primary source.
Study design and sample
Case report; Human.
Older adults with early Alzheimer's disease
- Design
- Case report
- Sample
- —
- Journal
- The University of Texas Health Science Center at San Antonio
- Published
- Mar 6, 2023
Effect size
Not recorded.
Caveats
- Assessment: Superseded.
- Only the source material recorded on this evidence page was assessed.
Conflicts and funding
Not recorded.
Previous evidence
See the Senolytics timeline and recorded assessment for prior evidence.
Primary source
Cancel Death charts and briefs may be reproduced editorially with attribution to CancelDeath.com. This brief is generated from the primary recorded source facts and assessment. Its review status is shown below; verify quotations against the paper before publication.